Anal

Archetype D 24 regimens (Main Regimens) anal

Squamous cell carcinoma of the anal canal and margin

DefinitionClick to collapse

Anal carcinoma is a malignancy arising from the anal region, which is divided into the anal canal and the perianal region. The functional anal canal, which is primarily used for radical surgical treatment, is defined by the sphincter muscles. Its superior border is the palpable upper border of the anal sphincter and puborectalis muscles of the anorectal ring, and its inferior border starts at the anal verge, the lowermost edge of the sphincter muscles corresponding to the introitus of the anal orifice. This functional canal is approximately 3 to 5 cm in length. The anatomic anal canal begins at the anorectal ring and extends to the anal verge (squamous mucocutaneous junction with the perianal skin). The perianal region starts at the anal verge and includes the perianal skin over a 5-cm radius from the squamous mucocutaneous junction [ANAL-1, footnote a; ANAL-2, footnote l; MS-6]. Histologically, the proximal anal canal is lined by glandular columnar epithelium, the middle zone by transitional epithelium, and the distal third by nonkeratinizing squamous epithelium, which merges with keratinized perianal skin at the anal margin [MS-6]. Lymphatic drainage patterns differ based on tumor location: distal tumors drain mainly to superficial inguinal nodes, while proximal tumors drain to perirectal and internal iliac nodes, though overlap occurs [MS-7].

EpidemiologyClick to collapse

An estimated 10,930 new cases (3,560 in males, 7,370 in females) of cancer involving the anus, anal canal, or anorectum were projected in the United States in 2025, accounting for approximately 3% of digestive system cancers [MS-2]. The incidence rate of invasive anal carcinoma in the U.S. increased by approximately 1.9-fold for males and 1.5-fold for females between the periods 1973–1979 and 1994–2000 and has continued to increase since that time. An analysis of SEER data showed the incidence of anal squamous carcinoma increased at a rate of 2.9% per year from 1992 to 2001. Another analysis reported an annual increase of 2.7% between 2001 and 2015, with the greatest increases in age groups ≥50 years [MS-2].
Annual Incidence
An estimated 2,030 deaths due to anal cancer were projected to occur in the United States in 2025 [MS-2]. Anal cancer mortality rates (2001–2016) rose with an average increase of 3.1% per year [MS-2].
Annual Mortality
The incidence has been steadily increasing over several decades. The increase in lymph node positivity on imaging over time is attributed partly to the use of more sensitive imaging techniques (the 'Will Rogers effect'), not necessarily a shift to more advanced stage at diagnosis [MS-9].
Trend & Projections
The disease is more common in females. Increases in incidence were especially noted for females ≥50 years of age [MS-2].
Demographics

SubtypesClick to collapse

Most primary cancers of the anal canal are of squamous cell histology.
Squamous Cell Carcinoma (SCC)

The most common histologic type of primary anal cancer. The WHO 5th edition classification includes various histologic patterns (previously designated as cloacogenic, basaloid, or transitional) under a single diagnosis of SCC, as they share similar natural history and prognosis. Distinction by cell type is not made in these guidelines [MS-7].

Rare; exact frequency not specified in the source.
Verrucous Carcinoma (VC)

A low-grade subtype of SCC characterized by marked exophytic and endophytic growth without features of HPV cytopathic effect or high-grade cytologic atypia on superficial biopsy. When conventional SCC is identified arising in VC, the diagnosis should be SCC as these lesions have similar biology [MS-7].

Seen with increasing frequency due to increased anal cancer screening [MS-16].
Superficially Invasive Squamous Cell Carcinoma (SISCCA)

A clinical-pathologic entity defined as anal cancer that has been completely excised, with ≤3-mm basement membrane invasion and a maximal horizontal spread of ≤7 mm (T1,NX). These are generally found incidentally in biopsies or excisions of benign lesions [ANAL-A; MS-16].

Molecular PathogenesisClick to collapse

The key molecular event in anal squamous cell carcinoma is infection with high-risk human papillomavirus (HPV), which is detected in 84% to 97% of anal cancer specimens [MS-2, MS-3]. The association with persistent infection by high-risk HPV forms, especially HPV-16 and HPV-18, is especially strong. A study found high-risk HPV DNA in 84% of anal cancer specimens (HPV-16 in 73%), while it was absent in rectal adenocarcinomas [MS-3]. The viral oncoproteins E6 and E7 from high-risk HPV types inactivate the tumor suppressor proteins p53 and pRb, respectively, leading to genomic instability and carcinogenesis. The guidelines do not detail specific frequencies of other driver mutations or chromosomal abnormalities beyond this HPV-driven pathway. Immunosuppression, as seen in HIV infection or after solid organ transplantation, is a critical co-factor that likely facilitates persistence of HPV infection [MS-3]. There is evidence that HPV- and/or p16-positivity are prognostic for improved overall survival, and p16-positivity was an independent prognostic factor for OS in one study (HR, 0.07; P = .016) [MS-8].

Risk FactorsClick to collapse

Human Papillomavirus (HPV) infection

Persistent infection with high-risk HPV (e.g., HPV-16, HPV-18) is the primary risk factor. High-risk HPV DNA is detected in 84%-97% of anal cancers [MS-3].

Human Immunodeficiency Virus (HIV) infection

People with HIV (PWH) have an approximately 15- to 35-fold increased likelihood of being diagnosed with anal cancer compared to the general population. The standardized incidence rate in the U.S. increased from 19.0 per 100,000 person-years (1992-1995) to 78.2 (2000-2003). Incidence is highest in men who have sex with men (MSM) with HIV (131 per 100,000 person-years) [MS-3].

Solid organ transplantation

Incidence rates rise with age and years since transplant. Rates can be as high as 24.5 and 29.6 per 100,000 person-years in males and females ≥10 years post-transplant, respectively [MS-3].

Receptive anal intercourse / sexually transmitted diseases

A history of receptive anal intercourse or sexually transmitted disease is a known risk factor [MS-3].

Smoking

Smoking is listed as an associated risk factor [MS-3].

Autoimmune disorders

Incidence rates of 10, 6, and 3 per 100,000 person-years have been reported for patients with systemic lupus erythematosus, ulcerative colitis, and Crohn’s disease, respectively [MS-3].

History of certain gynecologic cancers

A history of cervical, vulvar, or vaginal cancer, likely due to shared HPV risk [MS-3].

Male sex

Multivariate analyses have identified male sex as an independent prognostic factor for worse disease-free survival and overall survival [MS-8].

Clinical FeaturesClick to collapse

Typical Presentation

Anal carcinoma typically presents with rectal bleeding (approximately 45% of patients), pain, or the sensation of a rectal mass (approximately 30% of patients). The majority of primary cancers of the anal canal are of squamous cell histology. Superficially invasive squamous cell carcinoma (SISCCA) are anal cancers that are generally found incidentally in the setting of a biopsy or excision of what is thought to be a benign lesion such as a condyloma, hemorrhoid, or anal skin tag. Perianal squamous cell carcinomas are more likely than those of the anal canal to be well-differentiated and keratinizing large-cell types. The functional anal canal is approximately 3 to 5 cm in length, with its superior border defined as the palpable upper border of the anal sphincter and puborectalis muscles of the anorectal ring, and its inferior border starting at the anal verge, the lowermost edge of the sphincter muscles, corresponding to the introitus of the anal orifice. The perianal region starts at the anal verge and includes the perianal skin over a 5-cm radius from the squamous mucocutaneous junction.

Symptoms

45% of patients
Rectal bleeding

The most common presenting symptom, reported in approximately 45% of patients with anal carcinoma

30% of patients
Rectal pain

Approximately 30% of patients present with pain, which may be perianal or related to the anal mass

30% of patients
Rectal mass sensation

Approximately 30% of patients report a sensation of a rectal mass

Variable
Perianal skin lesion

Perianal cancers may present as discrete lesions arising from the perianal skin that can be visualized completely when the buttocks are gently pressed

Signs

Common in presenting patients
Palpable anal mass on digital rectal examination (DRE)

DRE is a critical component of the initial evaluation; T stage is primarily determined through clinical examination including DRE

6.4-16% depending on T stage
Inguinal lymphadenopathy

Inguinal lymph node evaluation is mandatory; synchronous inguinal node metastasis was observed in 6.4% of patients with T1/T2 tumors and 16% of patients with T3/T4 tumors

Variable
Perianal skin abnormality

Visible or palpable abnormality in the perianal region extending up to 5 cm from the squamous mucocutaneous junction

Common
Anal canal mass on anoscopy

Anoscopic examination is part of the standard workup to visualize the anal canal and obtain biopsy

Red FlagsClick to collapse

InvestigationsClick to collapse

Diagnostic

Biopsy (incisional, excisional, or punch biopsy)

Required for histologic confirmation of squamous cell carcinoma; definitive diagnosis; all primary cancers of the anal canal are of squamous cell histology in most cases

Digital rectal examination (DRE)

Essential component of the clinical evaluation; T stage is primarily performed through clinical examination

Anoscopy

Allows direct visualization of the anal canal and perianal region; facilitates biopsy

Inguinal lymph node evaluation (palpation ± biopsy/FNA)

Mandatory evaluation of regional lymph nodes; inguinal node metastasis is common especially with distal anal cancers

Staging

Chest/abdomen CT with IV and oral contrast + pelvis CT or MRI with contrast

Standard staging imaging for all patients; CT should be with IV and oral contrast; pelvis MRI with contrast provides superior soft tissue resolution for pelvic disease assessment

FDG-PET/CT or FDG-PET/MRI

Can be considered to verify staging before treatment; reported to be useful in evaluation of pelvic nodes even with normal-sized lymph nodes on CT; pooled sensitivity and specificity for detection of lymph node involvement reported as 93% and 76% respectively in a recent meta-analysis; FDG-PET/CT led to upstaging in 5% to 38% of patients and downstaging in 8% to 27% of patients; treatment plan modifications occurred in 12% to 59% of patients based on FDG-PET/CT results

Pelvic MRI with contrast

Provides superior soft tissue resolution compared to CT; recommended for pelvic staging

Chest CT without contrast

Intravenous contrast is not required for the chest CT; evaluates for pulmonary metastases since veins of the anal region are part of the venous network associated with systemic circulation

Biomarkers

HIV testing

Risk of anal carcinoma is 15- to 35-fold increased in people with HIV (PWH); approximately 13% of people in the United States infected with HIV are not aware of their infection status; identification of HIV infection has the potential to improve clinical outcomes

HPV/p16 testing

HPV- and/or p16-positivity are prognostic for improved overall survival in patients with anal carcinoma; in a retrospective study of 143 tumor samples, p16-positivity was an independent prognostic factor for OS (HR, 0.07; 95% CI, 0.01–0.61; P = .016); high-risk HPV DNA detected in 84% of anal cancer specimens in one study

MSI/MMR testing

MSI is uncommon in anal cancer; however, responses to PD-1/PD-L1 inhibitors occur in 20% to 24% of patients regardless of MSI status; anal cancers may respond due to high PD-L1 expression and/or high tumor mutational load despite being microsatellite stable

DPYD testing

FDA added a Boxed warning to the capecitabine label recommending testing for DPYD genetic variants prior to initiating capecitabine unless immediate treatment is necessary

StagingClick to collapse

AJCC Cancer Staging System, 9th Edition (2022)

T Categories

StageDescription
TXPrimary tumor not assessed
T0No evidence of primary tumor
T1Tumor less than or equal to 2 cm in greatest dimension
T2Tumor greater than 2 cm but less than or equal to 5 cm in greatest dimension
T3Tumor greater than 5 cm in greatest dimension
T4Tumor of any size invades adjacent organ(s), such as the vagina, urethra, or bladder

N Categories

StageDescription
NXRegional lymph nodes cannot be assessed
N0No tumor involvement of regional lymph node(s)
N1Tumor involvement of regional lymph node(s)
N1aTumor involvement of inguinal, mesorectal, superior rectal, internal iliac, or obturator lymph node(s)
N1bTumor involvement of external iliac lymph node(s)
N1cTumor involvement of N1b (external iliac) with any N1a node(s)

M Categories

StageDescription
cM0No distant metastasis
cM1Distant metastasis
pM1Microscopic confirmation of distant metastasis

Stage Groupings

GroupCriteriaClinical MeaningFive Yr SurvivalTreatment Intent
Stage IT1, N0, M0Small tumor (≤2 cm) limited to the anal canal without lymph node involvement or distant metastasisLocalized disease: 80% five-year survival (SEER data 1999-2006)Curative; for anal canal: chemoRT; for perianal: local excision if well/moderately differentiated T1N0 or select T2N0 not involving sphincter
Stage IIAT2, N0, M0Tumor >2 cm but ≤5 cm without lymph node involvement or distant metastasisLocalized disease: 80% five-year survivalCurative; chemoRT for anal canal; for perianal: local excision if select T2N0 not involving sphincter, otherwise chemoRT
Stage IIBT1–T2, N1, M0Small to moderate tumor with regional lymph node involvement but no distant metastasisRegional disease: 60% five-year survivalCurative; chemoRT
Stage IIIAT3, N0–N1, M0Large tumor (>5 cm) with or without regional lymph node involvement, no distant metastasisRegional disease: 60% five-year survivalCurative; chemoRT
Stage IIIBT4, N0, M0Tumor invading adjacent organs (vagina, urethra, bladder) without regional lymph node involvement or distant metastasisRegional disease: 60% five-year survival; worst prognosis among node-negative groupsCurative; chemoRT
Stage IIICT4, N1, M0Tumor invading adjacent organs with regional lymph node involvement, no distant metastasisRegional disease: 60% five-year survival; worst prognosis categoryCurative; chemoRT
Stage IVAny T, Any N, M1Any primary tumor with distant metastasisDistant metastasis: 30.5% five-year survivalPalliative; systemic therapy; chemoRT to primary site may be considered for local control

Staging Pearls

  • The AJCC 9th edition removed the former N2 and N3 categories by locations of positive nodes and introduced new categories N1a, N1b, and N1c based on specific nodal regions
  • N1a represents metastasis in inguinal, mesorectal, superior rectal, internal iliac, or obturator nodes; N1b represents external iliac nodes; N1c represents external iliac with any N1a nodes
  • Both anal canal and perianal tumors use the AJCC anus staging system (previously perianal cancer used the skin cancer staging system)
  • Prognosis is related to tumor size and lymph node metastases; male sex, positive lymph nodes, and tumor size >5 cm are independently prognostic for worse OS
  • The same staging system applies to both anal canal and perianal cancers to avoid undertreatment of perianal cancers that may involve the anal canal
  • T stage is primarily determined through clinical examination (DRE, anoscopy) rather than pathologic staging since primary treatment does not involve surgical excision
  • Para-aortic lymph nodes that can be included in a radiation field may be treated with definitive chemoRT, although only limited retrospective data support this use
  • Distal anal cancers present with a higher incidence of inguinal node metastases, but inguinal node metastases can occur in proximal anal cancer as well since lymphatic drainage systems are not isolated from each other
  • Five-year survival by stage: localized 80%, regional 60%, distant 30.5%

Management PrinciplesClick to collapse

Anal carcinoma is primarily managed with concurrent chemoradiation (chemoRT), a paradigm established after Nigro and colleagues observed complete tumor regression with preoperative 5-fluorouracil (5-FU)–based concurrent chemotherapy and radiation in 1974 [122]. Prior to this, patients with invasive anal carcinoma were routinely treated with abdominoperineal resection (APR); however, local recurrence rates were high, 5-year survival was only 40% to 70%, and morbidity with permanent colostomy was considerable [15]. The current treatment philosophy is organ-preserving: definitive chemoRT achieves cure in the majority of patients while avoiding permanent colostomy. All recommendations are category 2A unless otherwise indicated, reflecting uniform NCCN consensus based on lower-level evidence. Clinical trial participation is encouraged when applicable and available [NCCN]. The NCCN Guidelines Panel believes that a multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating individuals with anal carcinoma [MS-23]. Surgery (APR) is reserved for biopsy-proven recurrent or persistent disease following primary treatment, or for the small subset of very early lesions amenable to local excision. Systemic therapy is the backbone of treatment for metastatic disease, with recent evidence supporting the addition of immune checkpoint inhibitors to first-line chemotherapy [234].

Curative

Non-metastatic anal canal cancer (stage I–III, including positive para-aortic lymph nodes that can be included in the radiation field)

Concurrent chemoRT with mitomycin/5-FU, mitomycin/capecitabine, or cisplatin/5-FU (category 2B) [ANAL-1, ANAL-B 1 of 5]

Curative

T1N0 well or moderately differentiated or select T2N0 perianal cancer not involving the sphincter

Local excision with 1-cm margins; if margins adequate, observe; if margins inadequate, re-excision preferred or consider local RT ± chemotherapy [ANAL-2, ANAL-A]

Curative

T1N0 poorly differentiated or T2–T4 N0 or any T N+ perianal cancer

Local excision → re-excision (preferred) if inadequate margins, or consider local RT ± chemotherapy; OR definitive chemoRT as for anal canal cancer [ANAL-2]

Palliative

Metastatic anal carcinoma (any subsite)

First-line systemic therapy (preferred: carboplatin/paclitaxel + retifanlimab-dlwr); chemo/RT to the primary site may be considered for local control of symptomatic bulky primary [ANAL-1, ANAL-B 2 of 5, ANAL-C 4 of 6]

Salvage

Locally recurrent or persistent disease after prior chemoRT

APR with colostomy; immunotherapy (nivolumab, pembrolizumab, retifanlimab-dlwr, cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, toripalimab-tpzi, or penpulimab-kcqx) (category 2B) may be considered before proceeding to APR based on institutional experience [ANAL-3, ANAL-4]

A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating individuals with anal carcinoma [MS-23]. The oncologist and primary care provider should have defined roles in the surveillance period, with roles communicated to the patient [MS-23]. Modifications to cancer treatment should not be made solely based on HIV status; additional considerations for people with HIV (PWH) who have anal cancer are outlined in the NCCN Guidelines for Cancer in People with HIV, including the use of normal tissue-sparing radiation techniques, the consideration of non-malignant causes for lymphadenopathy, and the need for more frequent post-treatment surveillance anoscopy [ANAL-1 footnote i, MS-16].

The Panel notes that poor performance status in PWH and anal cancer may be from HIV, cancer, or other causes. The reason for poor performance status should be considered when making treatment decisions. Treatment with antiretroviral therapy (ART) may improve poor performance status related to HIV [MS-16]. For individuals with anal cancer who are not candidates for intensive therapy, the optimal chemotherapy regimen remains uncertain. Some NCCN Panel members have used a combination of weekly cisplatin and daily 5-FU on days of radiation for chemoRT in localized anal cancer. Other potential strategies may include capecitabine plus RT or RT alone (without chemotherapy). However, due to a lack of data supporting this approach and differing strategies among Panel members, recommendations have not yet been defined. Use of a geriatric assessment to guide management and elicitation of the patient's goals and objectives with regard to their cancer diagnosis is critical to inform shared decision-making [MS-15, MS-16].

Management PathwaysClick to collapse

Anal Canal Cancer — Locoregional Disease (± Positive Para-Aortic Lymph Nodes)

Branching: Anatomic site (anal canal), Clinical stage, Nodal involvement (including para-aortic nodes that can be included in radiation field)

Anal canal cancer, locoregional disease (± positive para-aortic lymph nodes that can be included in a radiation field) [ANAL-1]
Fluorouracil/mitomycin + radiation therapy (RT) (preferred); Capecitabine/mitomycin + RT (preferred); Cisplatin/fluorouracil + RT (other_recommended)
Perianal Cancer — T1N0 Well/Moderately Differentiated or Select T2N0 (Not Involving Sphincter)

Branching: Anatomic site (perianal), T stage, Nodal status, Histologic grade, Sphincter involvement, Surgical margin status

T1, N0 well or moderately differentiated or select T2, N0 perianal (anal margin) cancer that does not involve the sphincter [ANAL-2]
Local excision with adequate margins (1 cm) (preferred); Observe if margins are adequate (preferred); Re-excision if margins inadequate (preferred) (preferred); Consider local RT ± fluorouracil/mitomycin or capecitabine/mitomycin or cisplatin/fluorouracil (category 2B) (useful_in_certain_circumstances)
Perianal Cancer — T1N0 Poorly Differentiated, T2–T4 N0, or Any T N+ (± Para-Aortic Nodes)

Branching: Anatomic site (perianal), Histologic grade (poorly differentiated), T stage (T2–T4), Nodal status (N+), Para-aortic node involvement

T1, N0 poorly differentiated or T2–T4, N0 or any T, N+ perianal cancer (± positive para-aortic lymph nodes that can be included in radiation field) [ANAL-2]
Local excision → Re-excision (preferred) if margins inadequate (preferred); Consider local RT ± fluorouracil/mitomycin or capecitabine/mitomycin or cisplatin/fluorouracil (category 2B) (useful_in_certain_circumstances); Fluorouracil/mitomycin + RT (preferred); Capecitabine/mitomycin + RT (preferred); Cisplatin/fluorouracil + RT (other_recommended)
Metastatic Anal Carcinoma — First-Line Systemic Therapy

Branching: Disease status (metastatic), Prior therapy (treatment-naïve), HIV status, Performance status

Metastatic anal carcinoma, first-line therapy, treatment-naïve [ANAL-B 2 of 5]
Carboplatin/paclitaxel + retifanlimab-dlwr (preferred); CAPEOX (Capecitabine/Oxaliplatin) (other_recommended); Carboplatin/Paclitaxel (other_recommended); FOLFCIS (Leucovorin/Fluorouracil/Cisplatin) (other_recommended); FOLFOX (Leucovorin/Fluorouracil/Oxaliplatin) (other_recommended); Cisplatin/Fluorouracil (other_recommended); Modified DCF (Docetaxel/Cisplatin/Fluorouracil) (other_recommended)
Metastatic disease, chemo/RT to primary site for local control [ANAL-B 2 of 5]
Fluorouracil + RT (other_recommended); Capecitabine + RT (other_recommended)
Metastatic Anal Carcinoma — Second-Line and Subsequent Systemic Therapy

Branching: Prior immunotherapy received or not, Prior chemotherapy agents received, Response to first-line therapy

Metastatic anal carcinoma, second-line and subsequent therapy, no prior immunotherapy received [ANAL-B 2 of 5]
Cemiplimab-rwlc (preferred); Dostarlimab-gxly (preferred); Nivolumab (preferred); Pembrolizumab (preferred); Penpulimab-kcqx (preferred); Retifanlimab-dlwr (preferred); Tislelizumab-jsgr (preferred); Toripalimab-tpzi (preferred)
Metastatic anal carcinoma, second-line and subsequent therapy, if not previously given [ANAL-B 2 of 5]
CAPEOX (Capecitabine/Oxaliplatin) (other_recommended); Carboplatin/Paclitaxel (other_recommended); FOLFCIS (other_recommended); FOLFOX (other_recommended); Cisplatin/Fluorouracil (other_recommended); Modified DCF (Docetaxel/Cisplatin/Fluorouracil) (other_recommended)
Post-Chemoradiation Surveillance — Complete Remission

Branching: Response assessment at 8–12 weeks, Clinical stage at diagnosis (I–III), DRE and clinical evaluation

Complete remission after primary chemoRT, evaluated at 8–12 weeks with exam and DRE [ANAL-3]
DRE every 3–6 months for 5 years; inguinal node palpation every 3–6 months for 5 years; anoscopy every 6–12 months × 3 years; C/A/P CT with contrast or chest CT without contrast and abdomen/pelvis MRI with contrast annually for 3 years (stage II–III) (preferred)
Post-Chemoradiation — Persistent Disease Management

Branching: Clinical response at 8–12 weeks, Progression on serial exams vs regression/no progression, Duration of follow-up (up to 6 months)

Persistent disease at initial 8–12 week evaluation [ANAL-4]
Re-evaluate in 4 weeks (preferred)
Persistent disease with progression on serial exams [ANAL-4]
Biopsy proven → Restage → Locally recurrent: APR + groin dissection if positive inguinal nodes; Metastatic: First-line Systemic Therapy (preferred)
Persistent disease with regression or no progression on serial exams [ANAL-4]
Continue observation and re-evaluate at 3-month intervals; surveillance (ANAL-3) (preferred)
Locally Recurrent or Progressive Disease After Primary ChemoRT

Branching: Site of recurrence (primary site vs inguinal nodes), Prior radiation to the groin, Surgical candidacy, Metastatic workup

Biopsy-proven locally recurrent disease (primary site) [ANAL-3]
Abdominoperineal resection (APR) with colostomy; consider muscle flap reconstruction (preferred); Consider immunotherapy (nivolumab, pembrolizumab, retifanlimab-dlwr, cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, toripalimab-tpzi, or penpulimab-kcqx) (category 2B) before proceeding to APR (useful_in_certain_circumstances)
Inguinal node recurrence [ANAL-3]
RT if definitive radiation possible (preferred) (preferred); Carboplatin/paclitaxel + retifanlimab-dlwr (preferred); Groin dissection (preferred); First-line Systemic Therapy if metastatic disease present (preferred)
Metastatic Anal Carcinoma — Chemo/RT to Primary Site for Local Control

Branching: Synchronous local and metastatic disease, Performance status, Extent of metastatic disease

Previously untreated anal cancer presenting with synchronous local and metastatic disease [ANAL-C 4 of 6, MS-15]
Fluorouracil + RT (preferred); Capecitabine + RT (preferred)

Pretreatment EvaluationClick to collapse

Clinical Examination
Digital rectal examination (DRE)
Required for all patients [ANAL-1, ANAL-2]
Inguinal lymph node evaluation with palpation
Required for all patients [ANAL-1, ANAL-2]
Consider biopsy or fine needle aspiration (FNA) if suspicious inguinal nodes
Recommended if clinically or radiologically suspicious nodes are identified [ANAL-1, ANAL-2]
Anoscopic examination
Required for all patients [ANAL-1, ANAL-2]
Pathology
Biopsy confirming squamous cell carcinoma histology
Required for diagnosis. For melanoma histology, see NCCN Guidelines for Melanoma: Cutaneous; for adenocarcinoma, see NCCN Guidelines for Rectal Cancer [ANAL-1, ANAL-2]
HPV and/or p16 testing (prognostic)
HPV- and/or p16-positivity are prognostic for improved OS in patients with anal carcinoma. A retrospective study found p16-positivity was an independent prognostic factor for OS (HR, 0.07; 95% CI, 0.01–0.61; P = .016) [105, MS-8]
MSI/MMR testing
MSI/MMR testing is not required for treatment decisions. MSI is uncommon in anal cancer [253, MS-22]
DPYD testing
For information on DPYD testing and fluoropyrimidine-associated toxicity, see the NCCN Guidelines for Colon Cancer [ANAL-1 footnote c, ANAL-B 1 of 5 footnote a]
Imaging
Chest/abdomen CT with contrast
CT should be with IV and oral contrast. Intravenous contrast is not required for the chest CT [ANAL-1, ANAL-2 footnote e]
Pelvis CT or MRI
Pelvis MRI with contrast. If intravenous iodinated contrast material is contraindicated due to significant contrast allergy or renal failure, then MRI examination of the abdomen and pelvis with IV gadolinium-based contrast agent (GBCA) can be obtained in select patients [ANAL-1, ANAL-2 footnote e]
Consider FDG-PET/CT or FDG-PET/MRI
FDG-PET/CT scan does not replace a diagnostic CT. FDG-PET/CT performed skull base to mid-thigh. FDG-PET/CT is useful in the evaluation of pelvic nodes, even in patients with normal-sized lymph nodes on CT imaging [ANAL-1, ANAL-2 footnote f; 112-117]
Laboratory Testing
HIV testing if status unknown
HIV testing should be performed because the risk of anal carcinoma is higher in people with HIV (PWH). About 13% of people in the United States infected with HIV are not aware of their infection status [ANAL-1, MS-9; 108]
Complete blood count, chemistry panel
Standard pre-treatment laboratory assessment
DPYD genotyping
FDA added a Boxed warning to the capecitabine label, recommending to test patients for genetic variants of DPYD prior to initiating capecitabine unless immediate treatment is necessary [ANAL-1 footnote c]
Specialist Consultations
Gynecologic exam, including screening for cervical cancer
Suggested due to the association of anal cancer and HPV [ANAL-1, ANAL-2; 13]
Fertility risk discussion/counseling in appropriate patients
Patients of childbearing potential should be counseled that an irradiated uterus cannot carry a fetus to term. Information regarding sperm banking or oocyte, egg, or ovarian tissue banking should be provided prior to treatment [ANAL-1, ANAL-2, ANAL-C 5 of 6]
Distress assessment
Refer to the NCCN Distress Thermometer and Problem List, which includes social determinants of health [ANAL-1 footnote d, ANAL-2 footnote d]
Gynecologic exam for vaginal dilator counseling
Patients should be considered for vaginal dilators and instructed on the symptoms of vaginal stenosis [ANAL-C 5 of 6]
Functional Assessments
Performance status assessment
Critical for treatment planning, particularly in PWH where poor performance status may be from HIV, cancer, or other causes [MS-16]
Geriatric assessment for older adults
Use of a geriatric assessment to guide management and elicitation of the patient's goals and objectives is critical for shared decision-making [MS-15]

SurgeryClick to collapse

Surgery plays a limited but critical role in the management of anal carcinoma. The primary treatment for most anal canal cancers is organ-preserving concurrent chemoRT; surgery is reserved for (1) very early perianal lesions amenable to local excision, (2) biopsy-proven recurrent or persistent disease after primary chemoRT (APR), and (3) inguinal node recurrence (groin dissection) [MS-15, MS-19]. Radical surgery (APR) is the primary treatment for local recurrence/persistence following failed chemoRT [ANAL-A].

Local excision is used for SISCCA and select early perianal cancers with histologically negative margins [ANAL-A]

For SISCCA, local excision alone with a structured surveillance plan may represent adequate treatment in carefully selected patients followed by an experienced provider and/or team [ANAL-A, MS-16]

APR for anal cancer may require wider lateral perianal margins than are required for rectal cancer [ANAL-A, MS-19]

General principles for APR are similar to those for distal rectal cancer and include the incorporation of total mesorectal excision (TME) [ANAL-A, MS-19]

Reconstructive tissue flaps (vertical rectus or local myocutaneous flaps) should be considered due to poor perineal wound healing following prior RT [ANAL-A, MS-19; 227, 228]

For patients who have already received groin radiation, consider an inguinal node dissection [ANAL-A]

Groin dissection can be done with or without APR depending on whether disease is isolated to the groin or is in conjunction with recurrence/persistence at the primary site [ANAL-A, MS-19]

Procedures

Local Excision (for SISCCA)
Local Excision (for Perianal Cancer)
Abdominoperineal Resection (APR)
Inguinal Node Dissection

Radiation TherapyClick to collapse

Radiation therapy (RT) is a central component of definitive treatment for non-metastatic anal carcinoma, delivered concurrently with chemotherapy (chemoRT). The consensus of the NCCN Panel is that intensity-modulated RT (IMRT) is preferred over 3D conformal RT (3D-CRT) [ANAL-C 1 of 6, 193]. RT is also used for palliation of symptomatic recurrent or metastatic disease, and for oligometastatic disease (SBRT may be considered) [ANAL-C 1 of 6].

Principles

  • IMRT is preferred over 3D-CRT and requires expertise and careful target design to avoid reduction in local control by 'marginal miss' [ANAL-C 1 of 6, 3]
  • Image-guided RT (IGRT) with kilovoltage (kV) imaging or cone beam CT imaging should be routinely used during treatment with IMRT and SBRT [ANAL-C 1 of 6]
  • Consider SBRT for patients with oligometastatic disease [ANAL-C 1 of 6]
  • Avoid extension of overall chemoRT treatment time to improve progression-free survival [ANAL-C 5 of 6]
  • Fusion of MRI pelvis and/or FDG-PET/CT or FDG-PET/MRI with the simulation CT is recommended in defining local and regional target structures [ANAL-C 1 of 6]
  • Displacement of the external genitalia from the radiation field should be considered to minimize treatment dose [ANAL-C 1 of 6]
  • Patients are instructed to maintain a full bladder and, if possible, a rectum empty of stool and gas for simulation and treatment [ANAL-C 1 of 6]
  • A radiopaque marker should be placed at the anal verge and perianal skin involvement can be outlined with radio-opaque markers [ANAL-C 1 of 6]
  • The pelvic and inguinal nodes should be routinely treated in all patients [ANAL-C 2 of 6]
  • For patients with cT3/4 anal cancer, consider selective dose escalation to 53.2–59.4 Gy in 28–33 fractions [ANAL-C 3 of 6]

Dose Frameworks

NameTotal DoseDose Per FractionFractionsScheduleIndication
Standard Shrinking Field Technique (RTOG 98-11 based)50.4–59.4 Gy1.8–2.0 Gy28–335 days per weekStandard treatment for non-metastatic anal canal cancer. Low-risk elective nodal PTV: 30.6 Gy in 1.8 Gy fractions. High-risk elective nodal PTV: additional 14.4 Gy (total 45 Gy). Gross disease PTV: additional 5.4–14.4 Gy (total 50.4–59.4 Gy) [ANAL-C 3 of 6]
RTOG 0529 Simultaneous Integrated Boost (SIB)See table1.5–1.8 Gy28–305 days per weekDose-painted IMRT with SIB technique. T1,N0: Primary 50.4 Gy/28 fx at 1.8 Gy/fx, Nodal 42 Gy/28 fx at 1.5 Gy/fx. T2,N0: same as T1,N0. T3–4,N0: Primary 54 Gy/30 fx at 1.8 Gy/fx, Nodal 45 Gy/30 fx at 1.5 Gy/fx. T any,N+(≤3 cm): Primary 54 Gy/30 fx at 1.8 Gy/fx, Involved nodal 50.4 Gy/30 fx at 1.68 Gy/fx, Nodal 45 Gy/30 fx at 1.5 Gy/fx. T any,N+(>3 cm): Primary 54 Gy/30 fx at 1.8 Gy/fx, Involved nodal 54 Gy/30 fx at 1.8 Gy/fx, Nodal 45 Gy/30 fx at 1.5 Gy/fx [ANAL-C 3 of 6, Table 1]
Selective Dose Escalation for cT3/453.2–59.4 Gy1.8–2.0 Gy28–335 days per weekFor patients with cT3/4 anal cancer, consider selective dose escalation [ANAL-C 3 of 6]
Palliative RT20–30 GyN/A5–10Daily fractionsPure palliation for recurrent disease in previously irradiated fields. RT technique and doses are dependent on dosing and technique of prior treatment [ANAL-C 4 of 6]

Approaches

NameDose FractionationConcurrent ChemotherapyIndicationKey TrialToxicities
IMRT with Concurrent 5-FU/MitomycinPer RTOG 0529 or standard shrinking field techniqueFluorouracil 1000 mg/m2/day continuous infusion Days 1–4 and 29–32 + Mitomycin 10 mg/m2 IV bolus Days 1 and 29 (capped at 20 mg) or Mitomycin 12 mg/m2 IV bolus Day 1 (capped at 20 mg)Primary treatment of non-metastatic anal canal cancerRTOG 0529: Grade 2+ hematologic events reduced (73% vs 85%; P = .032), grade 3+ GI events reduced (21% vs 36%; P = .008), grade 3+ dermatologic events reduced (23% vs 49%; P < .0001) [189]. Long-term: 8-year OS 62%, 8-year DFS 62% [190].Grade 2+ combined acute adverse event rate was 77%. Grade ≥2 non-hematologic late toxicities rate was 15% [189, 190].
IMRT with Concurrent Capecitabine/MitomycinPer RTOG 0529 or standard shrinking field techniqueCapecitabine 825 mg/m2 PO BID Monday–Friday on days of radiation treatment only + Mitomycin 10 mg/m2 IV bolus Days 1 and 29 (capped at 20 mg) or Mitomycin 12 mg/m2 IV bolus Day 1 (capped at 20 mg)Primary treatment of non-metastatic anal canal cancer; alternative to 5-FU/mitomycinPhase II study found 6-month locoregional control rate of 86% (95% CI, 0.72–0.94) [142]. Retrospective study showed significantly lower grade 3/4 hematologic toxicities with capecitabine vs 5-FU [139].Grade 3/4 hematologic toxicities significantly lower compared to 5-FU-based regimen [139]
IMRT with Concurrent Cisplatin/5-FUPer standard techniqueCisplatin 75 mg/m2 IV Day 1 + continuous infusion Fluorouracil 1000 mg/m2/day IV Days 1–4, repeat every 4 weeksPrimary treatment of non-metastatic anal canal cancer (category 2B)ACT II trial demonstrated equivalence of cisplatin and mitomycin in chemoRT regimens [143]. RTOG 98-11 showed inferior 5-year DFS (57.8% vs 67.8%; P = .006) and 5-year OS (70.7% vs 78.3%; P = .026) for cisplatin-based regimen [100, 144].Higher toxicity compared to mitomycin-based regimen in RTOG 98-11 [100, 144]

Systemic TherapyClick to collapse

Systemic therapy serves two roles in anal carcinoma: (1) concurrent chemotherapy with radiation for non-metastatic disease, and (2) palliative systemic therapy for metastatic disease. For localized disease, mitomycin/5-FU or mitomycin/capecitabine with concurrent RT are preferred regimens, with cisplatin/5-FU as a category 2B alternative [ANAL-B 1 of 5]. For metastatic disease, carboplatin/paclitaxel plus the PD-1 inhibitor retifanlimab-dlwr is the preferred first-line regimen based on the phase 3 POD1UM-303/InterAACT2 trial showing improved PFS (9.30 vs 7.39 months; HR = 0.63; P = .0006) [234, ANAL-B 2 of 5]. PD-1/PD-L1 inhibitors are preferred options for second-line and subsequent therapy [ANAL-B 2 of 5, MS-21, MS-22].

Localized anal canal cancer — concurrent chemoradiation
Mitomycin is an important component of chemoRT; the phase III Intergroup study demonstrated lower colostomy rate (9% vs 22%; P = .002) and higher 4-year DFS (73% vs 51%; P = .0003) with 5-FU/mitomycin compared to 5-FU alone [132]. ACT II demonstrated equivalence of cisplatin and mitomycin in chemoRT [143].
Preferred: Fluorouracil/Mitomycin + RT or Capecitabine/Mitomycin + RT
Metastatic anal cancer — first-line
Phase 3 POD1UM-303/InterAACT2 trial: improved median PFS (9.30 vs 7.39 months; HR = 0.63; P = .0006) and favorable OS trend (29.2 vs 23.0 months) [234, MS-20].
Preferred: Carboplatin/Paclitaxel + Retifanlimab-dlwr
Metastatic anal cancer — first-line, chemo/RT to primary for local control
For symptomatic bulky primary tumors in metastatic setting [ANAL-C 4 of 6, MS-20]
Preferred: Fluorouracil + RT or Capecitabine + RT
Metastatic anal cancer — second-line and subsequent (no prior immunotherapy)
Response rates of 20–24% with PD-1/PD-L1 inhibitors in previously treated anal cancer [247, 248]. MSI/MMR testing is not required; responses occur even in MSS tumors [253, MS-22].
Preferred: Cemiplimab-rwlc, Dostarlimab-gxly, Nivolumab, Pembrolizumab, Penpulimab-kcqx, Retifanlimab-dlwr, Tislelizumab-jsgr, or Toripalimab-tpzi
Locally recurrent/persistent disease — prior to APR
Institutional experience has demonstrated that some patients receive a good response and can avoid surgery [ANAL-3 footnote p]
Preferred: Immunotherapy (nivolumab, pembrolizumab, retifanlimab-dlwr, cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, toripalimab-tpzi, or penpulimab-kcqx) (category 2B)

Key Regimens

Fluorouracil/Mitomycin + RT (localized)
Fluorouracil 1000 mg/m2/day IV continuous infusion Days 1–4 and 29–32 + Mitomycin 10 mg/m2 (capped at 20 mg) IV bolus Days 1 and 29
Fluorouracil/Mitomycin + RT — Alternative dosing (localized)
Fluorouracil 1000 mg/m2/day IV continuous infusion Days 1–4 and 29–32 + Mitomycin 12 mg/m2 (capped at 20 mg) IV bolus Day 1 (single dose)
Capecitabine/Mitomycin + RT (localized)
Capecitabine 825 mg/m2 PO BID Monday–Friday, on days of radiation treatment only, throughout duration of RT (typically 28–30 treatment days) + Mitomycin 10 mg/m2 (capped at 20 mg) IV bolus Days 1 and 29
Capecitabine/Mitomycin + RT — Alternative dosing (localized)
Capecitabine 825 mg/m2 PO BID Monday–Friday, on days of radiation treatment only, throughout duration of RT + Mitomycin 12 mg/m2 (capped at 20 mg) IV bolus Day 1 (single dose)
Cisplatin/Fluorouracil + RT (localized)
Cisplatin 75 mg/m2 IV Day 1 + Fluorouracil 1000 mg/m2/day IV continuous infusion Days 1–4
Carboplatin/Paclitaxel + Retifanlimab-dlwr (metastatic first-line preferred)
Carboplatin AUC 5 IV Day 1 + Paclitaxel 80 mg/m2 IV Days 1, 8, and 15 + Retifanlimab-dlwr 500 mg IV Day 1 (repeated every 28 days for 6 cycles, followed by 500 mg every 28 days for up to 7 cycles)
CAPEOX (metastatic first-line other recommended)
Oxaliplatin 130 mg/m2 IV Day 1 + Capecitabine 1000 mg/m2 PO twice daily Days 1–14
Carboplatin/Paclitaxel (metastatic first-line other recommended)
Carboplatin AUC 5 IV Day 1 + Paclitaxel 175 mg/m2 IV Day 1
FOLFCIS (metastatic first-line other recommended)
Cisplatin 40 mg/m2 IV over 30 minutes Day 1 (given concurrently with leucovorin) + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil 400 mg/m2 IV bolus Day 1, then 1000 mg/m2/day × 2 days (total 2000 mg/m2 over 46–48 hours) IV bolus then continuous infusion Day 1
FOLFOX (metastatic first-line other recommended)
Oxaliplatin 85 mg/m2 IV Day 1 + Leucovorin 400 mg/m2 IV Day 1 + Fluorouracil 400 mg/m2 IV bolus Day 1, then 1200 mg/m2/day × 2 days (total 2400 mg/m2 over 46–48 hours) IV bolus then continuous infusion Day 1
Cisplatin/Fluorouracil (metastatic)
Cisplatin 60 mg/m2 IV Day 1 + Fluorouracil 1000 mg/m2/day IV continuous infusion Days 1–4
Modified DCF (metastatic first-line other recommended)
Docetaxel 40 mg/m2 IV Day 1 + Cisplatin 40 mg/m2 IV Day 1 + Fluorouracil 1200 mg/m2/day × 2 days (total 2400 mg/m2 over 46–48 hours) IV continuous infusion Day 1
Cemiplimab-rwlc (metastatic second-line preferred)
Cemiplimab-rwlc 350 mg IV Day 1
Dostarlimab-gxly (metastatic second-line preferred)
Dostarlimab-gxly 500 mg IV Every 3 weeks for 4 doses, then 1000 mg every 6 weeks
Nivolumab (metastatic second-line preferred)
Nivolumab 240 mg IV Every 2 weeks
Pembrolizumab (metastatic second-line preferred)
Pembrolizumab 200 mg IV Every 3 weeks
Penpulimab-kcqx (metastatic second-line preferred)
Penpulimab-kcqx 200 mg IV Day 1
Tislelizumab-jsgr (metastatic second-line preferred)
Tislelizumab-jsgr 200 mg IV Day 1
Toripalimab-tpzi (metastatic second-line preferred)
Toripalimab-tpzi 3 mg/kg IV Day 1
Fluorouracil + RT (chemo/RT to primary for local control)
Fluorouracil 225 mg/m2 IV over 24 hours (continuous infusion) Daily on Days 1–5 or 1–7
Capecitabine + RT (chemo/RT to primary for local control)
Capecitabine 825 mg/m2 PO twice daily Monday–Friday, on days of radiation treatment only, throughout duration of RT (typically 28–30 treatment days)

Treatment Response AssessmentClick to collapse

Title

Post-Chemoradiation Response Assessment and Follow-Up

Timing

Patients are re-evaluated by DRE between 8 and 12 weeks after completion of chemoRT [ANAL-3, MS-18].

Imaging Recommendations
  • FDG-PET/CT is not indicated in routine surveillance [ANAL-3, ANAL-4]

  • C/A/P CT with contrast or chest CT without contrast and abdomen/pelvis MRI with contrast annually for 3 years (stage II–III) [ANAL-3]

  • DRE every 3–6 months for 5 years [ANAL-3]

  • Inguinal node palpation every 3–6 months for 5 years [ANAL-3]

  • Anoscopy every 6–12 months × 3 years [ANAL-3]

Biopsy Or Salvage Logic
  • Evidence of progression found on DRE should be followed by biopsy as well as restaging with CT and/or FDG-PET/CT imaging [MS-19, ANAL-4]

  • Use imaging studies as per initial workup for restaging [ANAL-4 footnote s]

  • The Panel recommends against the use of FDG-PET/CT imaging as part of the reevaluation strategy for persistent disease due to concerns for false-positivity from local inflammation from RT leading to unnecessary surgeries [MS-18]

  • Patients with biopsy-proven locally progressive disease are candidates for radical surgery with an APR and colostomy [MS-19]

SurveillanceClick to collapse

Clinical Follow Up Schedule

  • Post-primary chemoradiation (complete remission):
  • - Digital rectal examination (DRE) every 3-6 months for 5 years.
  • - Inguinal lymph node palpation every 3-6 months for 5 years.
  • - Anoscopy every 6-12 months for 3 years.
  • Post-APR for recurrence/persistence:
  • - DRE and inguinal node palpation every 3-6 months for 5 years.
  • - Anoscopy every 6-12 months for 3 years (consider if anal canal not removed).

Imaging Strategy

  • For stage II-III disease after primary treatment:
  • - Annual chest/abdomen/pelvis CT with contrast OR chest CT without contrast and abdomen/pelvis MRI with contrast for 3 years.
  • For post-APR or following treatment of recurrence:
  • - Annual chest/abdomen/pelvis CT with contrast OR chest CT without contrast and abdomen/pelvis MRI with contrast for 3 years.
  • FDG-PET/CT is NOT routinely indicated for surveillance due to concerns for false-positivity from post-treatment inflammation.

Laboratory Monitoring

  • No specific serum tumor markers are routinely recommended for surveillance.
  • HIV testing: If HIV status is unknown at diagnosis, testing is recommended. For known HIV-positive patients, management should follow NCCN Guidelines for Cancer in People with HIV.

Supportive Follow Up

  • Fertility counseling and discussion of long-term effects of treatment (sexual function, bowel/bladder function).
  • Referral to pelvic floor rehabilitation if needed for bowel or urinary dysfunction.
  • Ostomy care coordination and support group referral if applicable.
  • Bone density monitoring as indicated for post-RT patients.
  • Smoking cessation counseling per NCCN Guidelines for Smoking Cessation.

ComplicationsClick to collapse

Disease-Related

ComplicationManagement
Locoregional recurrenceBiopsy-proven recurrence is treated with salvage abdominoperineal resection (APR). For isolated inguinal node recurrence, inguinal node dissection is recommended. Palliative RT or systemic therapy can be considered for symptomatic control.
Distant metastasis (most common sites: liver, lung, extrapelvic nodes)Treated with systemic therapy. Palliative RT to the primary site can be considered for local control following upfront chemotherapy.

Supportive CareClick to collapse

Supportive care is integral throughout the treatment and survivorship continuum, aiming to manage treatment toxicities, preserve function, and optimize quality of life. A multidisciplinary approach involving oncology, surgery, radiation, gastroenterology, urology, gynecology, and supportive care specialists is essential.

Nutritional Support

Nutritional status should be monitored, as pelvic radiotherapy can cause malabsorption and diarrhea. Diet manipulation (e.g., low-fiber for diarrhea, bulk-forming agents for incontinence) and potential referral to a nutritionist are recommended. Role of nutritional intervention in managing gastrointestinal symptoms post-pelvic RT is noted.

Anti Emetic Protocol

Antiemetics are used based on the emetogenic potential of the chemotherapy regimen. Platinum-based (cisplatin) and mitomycin regimens are moderately to highly emetogenic and require prophylaxis per antiemetic guidelines.

Gcsf Guidance

Growth factor support (G-CSF) may be considered for regimens with high risk of febrile neutropenia or for patients with prior episodes of severe neutropenia.

Vte Prophylaxis

VTE prophylaxis should be considered per institutional guidelines for hospitalized patients or those with additional risk factors.

Pain Management

Pain should be assessed and managed appropriately. This may include analgesics for acute treatment-related pain (e.g., proctitis) and management of chronic pain syndromes.

Psychosocial Support

Distress screening using tools like the NCCN Distress Thermometer is recommended at diagnosis and during follow-up. Support for issues related to body image changes, sexual dysfunction, ostomy management, and fear of recurrence should be provided. Referral to social work, psychology, or support groups is beneficial.

Dental Care

Dental evaluation prior to chemoradiation is recommended to address potential oral complications, especially with regimens affecting mucosal integrity.

PrognosisClick to collapse

Anal carcinoma prognosis is variable and stage-dependent, with a generally favorable outlook for localized disease but poorer outcomes for advanced or metastatic presentations. The prognosis is influenced by primary tumor size, lymph node status, HIV status, and HPV/p16 expression. Achieving a complete clinical response after primary chemoradiation is the strongest predictor of favorable long-term outcomes.

By Stage

StageFive Yr SurvivalContext
Localized (SEER 1999-2006 data)80%Approximately 50% of anal carcinomas are localized at diagnosis.
Regional Lymph Node Metastasis60%About 29% of patients present with regional nodal disease.
Distant Metastatic Disease30.5%Approximately 12% of patients present with metastatic disease.

Prognostic Factors

  • Tumor size: Larger tumor size (>5 cm) is an independent adverse prognostic factor for overall survival (OS) and colostomy rate.
  • Nodal status: Positive lymph nodes are associated with worse disease-free survival (DFS) and OS. Among node-positive patients, survival is related more to T-stage than nodal burden, with 5-year survival rates of 72.7% and 39.9% for T1-T2 vs. T3-T4 tumors.
  • Sex: Male sex is an independent prognostic factor for worse DFS and OS.
  • HPV/p16 status: HPV- and/or p16-positivity are associated with improved OS (p16-positive: HR, 0.07; 95% CI, 0.01–0.61; P = .016).
  • Response to therapy: Complete clinical response (CCR) at 26 weeks post-treatment is strongly associated with superior 5-year survival. Persistent disease may continue to regress up to 6 months post-chemoradiation.
  • HIV status: While most studies show similar efficacy of chemoradiation in HIV-positive vs. negative patients, some data suggest a greater risk of grade ≥3 cutaneous toxicities (RR = 1.34) and worse 3-year DFS (RR = 1.32) and OS (RR = 1.77) in people living with HIV.

Follow UpClick to collapse

Post Curative Treatment

Following curative-intent chemoradiation, patients are evaluated 8-12 weeks post-treatment with DRE to assess response. Based on the ACT-II study, patients with persistent disease (not complete response) without progression may be observed for up to 6 months, as continued regression can occur. Re-evaluation is performed every 4 weeks until progression or regression/no progression is confirmed. For complete remission, transition to a structured surveillance program is initiated.

Surveillance Rationale

The goal of surveillance is to detect recurrence early, when additional curative-intent treatment (e.g., salvage surgery, re-irradiation) may still be possible. Late recurrences can occur, warranting long-term monitoring. The intensity of surveillance is highest in the first 3-5 years, corresponding to the peak risk period for recurrence.

Late Effects Screening

  • Bowel function: Screen for chronic diarrhea, incontinence, urgency, stool clustering, and cramping.
  • Urogenital dysfunction: Screen for sexual dysfunction (erectile dysfunction, dyspareunia, vaginal stenosis, dryness), urinary incontinence, frequency, and urgency.
  • Bone health: Consider bone density monitoring for patients who received pelvic RT, given increased fracture risk.
  • Second primary cancers: Encourage age- and gender-appropriate cancer screenings (e.g., cervical, breast, colorectal).
  • Psychosocial and functional: Screen for distress, fatigue, and impacts on quality of life.

Recurrence Patterns

Recurrence patterns are often locoregional (10-30% locoregional failure rate after primary chemoradiation). Higher T and N stage are associated with higher recurrence rates. Most recurrences occur within the first 3 years, but late recurrences are possible. Metastatic recurrence most commonly involves the liver, lungs, and extrapelvic lymph nodes.

Key TrialsClick to collapse

AcronymFull NameYearNInterventionComparatorPopulationPrimary EndpointKey ResultSecondary OutcomesPractice ChangeJournal
EORTC 22861European Organization for Research and Treatment of Cancer Trial 228611997103Concurrent chemoradiation (5-FU + mitomycin + RT)Radiation therapy aloneLocally advanced anal carcinoma5-year locoregional controlChemoradiation superior: 18% higher locoregional control rate and 32% longer colostomy-free interval at 5 years.No significant difference in OS at 5 years.Established chemoradiation as superior to radiation alone for locally advanced anal cancer.Journal of Clinical Oncology
ACT I (UKCCCR)UK Coordinating Committee on Cancer Research Anal Cancer Trial I1996585Chemoradiation (5-FU + mitomycin + RT)Radiation therapy aloneLocally advanced anal carcinomaLocoregional failureChemoradiation superior for local control (RR, 0.54; 95% CI, 0.42–0.69; P < .0001). 13-year follow-up showed OS benefit (HR, 0.67; 95% CI, 0.51–0.88; P = .004).Improved colostomy-free survival.Confirmed chemoradiation as standard of care over radiation alone.The Lancet
RTOG 98-11Radiation Therapy Oncology Group 98-112008682Induction 5-FU/cisplatin followed by concurrent chemoRT (5-FU/cisplatin)Concurrent chemoRT (5-FU/mitomycin)Locally advanced anal carcinoma5-year disease-free survival (DFS)5-FU/mitomycin superior: 5-year DFS 67.8% vs. 57.8% (P = .006). 5-year OS also superior (78.3% vs. 70.7%; P = .026).5-year colostomy-free survival trended better with mitomycin (71.9% vs. 65.0%; P = .05).Established 5-FU/mitomycin as the standard concurrent chemotherapy regimen over 5-FU/cisplatin. Suggested induction chemotherapy is detrimental.Journal of Clinical Oncology
ACT IIAnal Cancer Trial II2013940Two factorial: 1) Cisplatin-based vs. Mitomycin-based chemoRT; 2) Maintenance chemo (5-FU/cisplatin) vs. no maintenanceSee interventionAnal squamous cell carcinomaComplete response rate (chemoRT comparison); Progression-free survival (maintenance comparison)No difference between cisplatin and mitomycin arms. No benefit for maintenance chemotherapy.No difference in colostomy rates. 72% of patients without complete response at 11 weeks achieved it by 26 weeks.Cisplatin is an acceptable alternative to mitomycin. Maintenance chemotherapy is not recommended. Established that persistent disease can regress for up to 6 months.The Lancet Oncology
RTOG 0529Radiation Therapy Oncology Group 0529201352Dose-painted IMRT with concurrent 5-FU/mitomycinHistorical control (3D-CRT from RTOG 98-11)Anal carcinoma treated with IMRTGrade ≥2 combined acute genitourinary and gastrointestinal adverse eventsDid not meet primary endpoint (77% vs. 77%). However, significant reductions in grade ≥2 hematologic (73% vs. 85%; P = .032), grade ≥3 GI (21% vs. 36%; P = .008), and grade ≥3 dermatologic (23% vs. 49%; P < .0001) toxicities.Long-term: 4-year OS 85.5%, 8-year OS 68%, 8-year DFS 62%.Demonstrated reduced acute toxicity with IMRT, leading to its preferred status over 3D-CRT for anal cancer treatment.International Journal of Radiation Oncology, Biology, Physics
InterAACTInternational Rare Cancers Initiative Multicenter Randomized Phase II Trial202091Carboplatin + paclitaxelCisplatin + 5-FUAdvanced/metastatic anal squamous cell carcinoma, first-lineResponse rateSimilar response rates (59% vs. 57%). Carboplatin/paclitaxel had lower grade ≥3 toxicity (71% vs. 76%) and fewer serious adverse events (36% vs. 62%; P = .016).Median PFS 8.1 vs. 5.7 months. Median OS 20 vs. 12.3 months (HR, 2.0; 95% CI, 1.15–3.47; P = .014).Established carboplatin/paclitaxel as a less toxic and potentially more effective first-line regimen than cisplatin/5-FU for metastatic anal cancer.Journal of Clinical Oncology
POD1UM-303/InterAACT2Phase 3 study of retifanlimab with carboplatin-paclitaxel in patients with inoperable locally recurrent or metastatic SCAC2024315Carboplatin/paclitaxel + retifanlimab-dlwrCarboplatin/paclitaxel + placeboFirst-line metastatic/inoperable locally recurrent anal squamous cell carcinomaProgression-free survival (PFS)PFS improved: median 9.30 months (95% CI, 7.5–11.3) vs. 7.39 months (95% CI, 7.1–7.7); HR = 0.63; P = .0006.OS trended favorable: 29.2 months vs. 23.0 months.Established carboplatin/paclitaxel + retifanlimab as the new preferred first-line regimen for metastatic anal cancer.Annals of Oncology (abstract)
KEYNOTE-158Pembrolizumab in patients with previously treated advanced anal squamous cell carcinoma2022112 (cohort A)PembrolizumabNone (single-arm)Previously treated advanced anal squamous cell carcinomaObjective response rate (ORR)ORR 11% (95% CI, 6–18). Higher in PD-L1-positive (15%) vs. PD-L1-negative (3%).Disease control rate 58%.Supported use of pembrolizumab in second-line metastatic anal cancer, regardless of PD-L1 status.The Lancet Gastroenterology & Hepatology
NCI9673Nivolumab for previously treated unresectable metastatic anal cancer201737NivolumabNone (single-arm)Refractory metastatic anal cancerResponse rateResponse rate 24% (95% CI, 15–33). Two complete responses.Manageable toxicity (13% grade 3 AEs).Provided early evidence for checkpoint inhibitor activity in anal cancer, leading to inclusion of nivolumab as a second-line option.The Lancet Oncology
ANCHORAnal Cancer HSIL Outcomes Research20224459Topical or ablative treatment of HSILActive monitoring with HRA every 6 monthsPeople living with HIV with anal high-grade squamous intraepithelial lesions (HSIL)Incident anal cancerTreatment reduced progression to anal cancer by 57% (95% CI, 6–80; P = .03). 9 vs. 21 cancer cases in treatment vs. monitoring groups.Progression rate from HSIL to cancer was 402/100,000 person-years with monitoring.Provides high-level evidence supporting treatment of anal HSIL to prevent anal cancer in high-risk populations.New England Journal of Medicine

Clinical PearlsClick to collapse

  • Pearl 1: The superior border of the functional anal canal (anorectal ring) separates it from the rectum. Tumors that cannot be entirely seen when buttocks are pressed are anal canal cancers; those that can be visualized are perianal cancers.
  • Pearl 2: Concurrent chemoradiation is the standard of care for locoregional anal carcinoma, avoiding the morbidity of a permanent colostomy associated with primary APR.
  • Pearl 3: Mitomycin is a critical component of the concurrent chemoradiation regimen. The phase III Intergroup study showed a lower colostomy rate (9% vs. 22%) and higher 4-year DFS (73% vs. 51%) with mitomycin/5-FU vs. 5-FU alone.
  • Pearl 4: The ACT-II trial showed no benefit of maintenance chemotherapy or replacement of mitomycin with cisplatin in the chemoRT regimen. Importantly, it also demonstrated that persistent disease may continue to regress up to 26 weeks from treatment start.
  • Pearl 5: IMRT is preferred over 3D conformal RT to reduce acute toxicities (especially dermatologic and gastrointestinal) without compromising local control, as demonstrated in RTOG 0529.
  • Pearl 6: The POD1UM-303/InterAACT2 trial established carboplatin/paclitaxel + retifanlimab as the new preferred first-line regimen for metastatic anal cancer, showing improved PFS over chemotherapy alone.
  • Pearl 7: HPV vaccination is recommended for prevention of anal HPV infection and related lesions. The 9-valent vaccine (Gardasil 9) is now the standard, with demonstrated efficacy in preventing HPV-6/11/16/18-related disease.
  • Pearl 8: For patients with persistent disease post-chemoradiation without progression, observation for up to 6 months is appropriate, as complete responses can still be achieved, potentially avoiding an APR.

Special SituationsClick to collapse

People with HIV/AIDS
Persistent Disease After Chemoradiation
Locoregional Recurrence
Metastatic Anal Cancer
Superficially Invasive Squamous Cell Carcinoma (SISCCA)
Perianal Cancer (T1, N0, Well/Moderately Differentiated)

Guidelines ResourcesClick to collapse

NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma
NCCN Guidelines for Cancer in People with HIV
NCCN Guidelines for Survivorship
NCCN Guidelines for Distress Management
NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities
NCCN Guidelines for Colon Cancer
Consensus Guidelines for Anal Cancer Screening
AJCC Cancer Staging Manual, 9th Edition

Protective FactorsClick to collapse

  • HPV vaccination (quadrivalent or 9-valent vaccine). A substudy showed 77.5% observed efficacy for the quadrivalent vaccine in preventing high-grade anal intraepithelial neoplasia in men who have sex with men [MS-5].
  • Antiretroviral therapy (ART) for HIV: Some evidence suggests prolonged ART (>24 months) may be associated with a decrease in the incidence of high-grade anal intraepithelial neoplasia [MS-4].